PTG1 and PTG3 are cationic polymers with histidine that provide highly efficient DNA transfection of different types of mammalian cells with low toxicity.
PTG1-plus is a BPF certified PTG1 derivative that is very efficient for the bioproduction of recombinant proteins and viruses (AAV and Lentiviruses) obtained from transient transfection of HEK293 and CHO-S cells.
A protocol has been developed for the bioproduction of AAV and Lentiviruses on an industrial scale in bioreactors of 200 to 400 liters. The production of viruses with PTG1-plus is much more effective than that obtained with competing transfection reagents, particularly with respect to the high level of complete viral particles.
This scaling up is essential to hope to reduce the costs of production and achieve more reasonable drug prices.
The results were presented at the annual conference of the European Society of Genetic and Cell Therapy (ESGCT) held in Barcelona from 22 to 25 October 2019. Poster P063 and P082
Following these results, Genethon has entered into a license agreement for the use of PTG1-plus. Yposkesi, the leader in Europe for the large-scale production of viral vectors for gene therapy, has also concluded a contract to supply PTG1-plus.